<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01007435</url>
  </required_header>
  <id_info>
    <org_study_id>WA19926</org_study_id>
    <secondary_id>2009-012759-12</secondary_id>
    <nct_id>NCT01007435</nct_id>
  </id_info>
  <brief_title>A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission and Prevention of Structural Joint Damage During Treatment With Tocilizumab (TCZ), as a Monotherapy and in Combination With Methotrexate (MTX), Versus Methotrexate in Patients With Early, Moderate to Severe Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, double-blind, parallel group study will assess the safety, disease
      remission, and prevention of structural joint damage in patients with early moderate to
      severe rheumatoid arthritis treated with tocilizumab as monotherapy or in combination with
      methotrexate, versus methotrexate alone. Patients will be randomized to receive either (A)
      tocilizumab (8 mg/kg iv every 4 weeks) plus placebo, (B) tocilizumab (8 mg/kg iv every 4
      weeks) plus methotrexate (7.5-20 mg po weekly), (C) tocilizumab (4 mg/kg iv every 4 weeks)
      plus methotrexate (7.5-20 mg po weekly), or (D) placebo plus methotrexate (7.5-20 mg po
      weekly). Patients in groups C and D who have not achieved low disease activity at week 52 can
      receive tocilizumab 8 mg/kg iv every 4 weeks. Anticipated time on study treatment is 104
      weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2009</start_date>
  <completion_date type="Actual">January 28, 2014</completion_date>
  <primary_completion_date type="Actual">May 31, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>A participant has a DAS28 remission response if their DAS28 &lt; 2.6. The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 52</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Weeks 24 and 52</measure>
    <time_frame>Baseline to Weeks 24 and 52</time_frame>
    <description>Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line &quot;no disease activity&quot; [symptom-free and no arthritis symptoms] and the extreme right end &quot;maximum disease activity&quot;; patient assessment of pain in previous the 24 hours on a VAS (extreme left end of the line &quot;no pain&quot; and the extreme right end &quot;unbearable pain&quot;); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint, including subluxation, is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Sharp Erosion Score at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sharp Joint Space Narrowing Score at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Major Clinical Response at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>A major clinical response is defined as an ACR70 response that is maintained for 6 consecutive months (24 weeks) for any 24-week period between Week 2 and Week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Weeks 24 and 52</measure>
    <time_frame>Baseline to Weeks 24 and 52</time_frame>
    <description>The Stanford HAQ-DI is a patient completed questionnaire specific for rheumatoid arthritis. The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short Form 36 (SF-36) Physical Component Summary (PCS) Scores at Weeks 24 and 52</measure>
    <time_frame>Baseline to Weeks 24 and 52</time_frame>
    <description>The SF-36 Health Survey (Version 2) is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1162</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>(A) Tocilizumab 8 mg/kg + placebo to methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(B) Tocilizumab 8 mg/kg + methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(C) Tocilizumab 4 mg/kg + methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(D) Placebo to tocilizumab + methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab was supplied in vials.</description>
    <arm_group_label>(A) Tocilizumab 8 mg/kg + placebo to methotrexate</arm_group_label>
    <arm_group_label>(B) Tocilizumab 8 mg/kg + methotrexate</arm_group_label>
    <arm_group_label>(C) Tocilizumab 4 mg/kg + methotrexate</arm_group_label>
    <other_name>RoActemra</other_name>
    <other_name>Actemra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to tocilizumab</intervention_name>
    <description>Placebo to tocilizumab was supplied in vials.</description>
    <arm_group_label>(D) Placebo to tocilizumab + methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.</description>
    <arm_group_label>(B) Tocilizumab 8 mg/kg + methotrexate</arm_group_label>
    <arm_group_label>(C) Tocilizumab 4 mg/kg + methotrexate</arm_group_label>
    <arm_group_label>(D) Placebo to tocilizumab + methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to methotrexate</intervention_name>
    <description>Patients received placebo to methotrexate orally once a week.</description>
    <arm_group_label>(A) Tocilizumab 8 mg/kg + placebo to methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients ≥ 18 years of age.

          -  Rheumatoid arthritis of ≤ 2 years duration.

          -  Disease Activity Score 28 (DAS28) &gt; 3.2.

          -  Swollen joint count (SJC) ≥ 4 of 66 joints, tender joint count (TJC) ≥ 6 of 68 joints.

          -  Rheumatoid factor (RF) and/or anti−cyclic citrullinated peptide (anti-CCP) positive
             (if RF and anti-CCP negative &gt; 1 erosion required at screening).

          -  Erythrocyte sedimentation rate (ESR) ≥ 28 mm/h or C-reactive protein (CRP) ≥ 10 mg/L
             at screening.

        Exclusion Criteria:

          -  Previous treatment with tocilizumab.

          -  Previous treatment with methotrexate or biologic agent.

          -  Rheumatic autoimmune disease other than rheumatoid arthritis (RA).

          -  History of or current inflammatory joint disease other than RA.

          -  Functional class IV as defined by the American College of Rheumatology (ACR)
             Classification of Functional Status in RA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group; Llc, Central</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of North Alabama</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clnical &amp; Translational Reseach Center for Alabama, PC</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthrocare, Arthritis Care and Research, P.C.</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Valley Arthritis Center</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Talbert Medical Group</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni of California - San Diego; Division of Rheumatology</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valerius Medical Group &amp; Research Ctr of Greater Long Beach</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Rees-Stealy Medical Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Arthritis Med Clnc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230-7127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joao Nascimento</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Research Associates</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis/Osteoporosis Treatment Center</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center Palm Harbor</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Rsrch of Florida, Inc.</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burnette &amp; Silverfield, MDS</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quad City Rheumatology, Sc</name>
      <address>
        <city>Moline</city>
        <state>Illinois</state>
        <zip>61265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Bone &amp; Joint Inst.</name>
      <address>
        <city>Morton Grove</city>
        <state>Illinois</state>
        <zip>60053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Clinic</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deerbrook Medical Associates</name>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <zip>60061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician'S Clinic of Iowa</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Christi Clinic, PA</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baton Rouge Clinic, Amc</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osteoporosis &amp; Clinical Trials Center</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Rheumatology</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiechtner Research Inc</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor Arthritis Center</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Inst. ; Rtrc</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Arthritis Clinic</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Ctr; Internal Medicine Associates</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Depaul Medical Group-SSM Healthcare</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center, Rheumatology 5C</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NJP Clinical Research</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mark Fisher Md, Facr, Llc</name>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <zip>08035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Center For Rheumatology</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis Associates of New Mexico</name>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <zip>88011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Health Associates; Clinical Research</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asheville Arthritis &amp; Osteoporosis Center, PA</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham Rheumatology</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University; Dept of Immunology</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Rheumatology &amp; Research Group, LLC</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Oklahoma, Llc</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Medical Research Foundation</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Consultants</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Penn Rheumatology Associates, Pc</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center For Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Reading</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Arthritis Clinic</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amarillo Center For Clinical Research</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Inst. For Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Associates, LLP</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Arthritis Research Center; Center for Arthritis &amp; Rheumatic Diseases</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Research Center</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Clinic</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest, Spokane</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tacoma Center For Arthritis Research</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Hospital &amp; Clinics</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatic Disease Center</name>
      <address>
        <city>Glendale</city>
        <state>Wisconsin</state>
        <zip>53217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Organizacion Medica de Investigacion</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. de Rehabilitacion Psicofisica; Reumathology</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1428DQG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caici; Rheumatology</name>
      <address>
        <city>Rosario</city>
        <zip>S2000PBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado de Reumatologia; Reumathology</name>
      <address>
        <city>San Miguel</city>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital; Rheumatology</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast Rheumatology Research Unit</name>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital; Rheumatology</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menzies Research Institute</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7100</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Medical Centre; Rheumatology</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worthing Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lkh innsbruck - univ. Klinikum innsbruck - Tiroler landeskrankenanstalten ges.m.b.h.; Innere Medizin</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Franz Josef Spital; Ii. Medizinische Abt.</name>
      <address>
        <city>Wien</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der stadt wien hietzing; ii. Med. Abt. / zentrum für rheumatologie</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Internacional de Pesquisa; Reumatologia</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74110010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - UFG;Reumatologia</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74653-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Mineiro de Pesquisa - CMIP</name>
      <address>
        <city>Juiz de Fora</city>
        <state>MG</state>
        <zip>36036-330</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos em Terapias Inovadoras - CETI</name>
      <address>
        <city>Curtiba</city>
        <state>PR</state>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas - PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital e Maternidade Celso Pierro - PUCCamp; Reumatologia</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13059-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Sao Paulo - UNIFESP; Reumatologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04026-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Paulista de Investigacao Clinica - CEPIC</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Research Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurel Medical Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research Centre</name>
      <address>
        <city>St John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. William G. Bensen Medicine Professional Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K-W Musculoskeletal Research</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2M 5N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph'S Health Care Centre; Rheumatology</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research Associates</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagara Peninsula Arthritis Centre</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2N 7E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve- Rosemont; Rheumatology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Rhumatologie de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Musculo-Squelettique</name>
      <address>
        <city>Trois-rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Osteoporosis Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 0H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Re Recherche Saint-Louis</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>10029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Chinese PLA; Department of Hematology</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riesgo De Fractura; Rheumatology</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin-Antioquia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumalab Sas; Rheumatology</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sjællands Universitetshospital, Køge; Reumatologisk Afdeling</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital; Rheumatology Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiljavan Lääketutkimus Oy</name>
      <address>
        <city>Hyvinkää</city>
        <zip>05800</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Jean Rougier; Rhumato Reed Fonctionnelle</name>
      <address>
        <city>Cahors</city>
        <zip>46005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Hopital Saint Joseph; Rhumatologie</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lapeyronie; Immunologie Rhumatologie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital emile muller; Rhumatologie</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Porte Madeleine; Service de Rhumatologie</name>
      <address>
        <city>Orleans</city>
        <zip>45032</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Pitie Salpetriere; Rhumatologie</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Purpan; Rhumatologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik; Rheumatologie&amp;klin.Immunologie</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheuma-Zentrum Baden-Baden Gmbh; Klinik Für Innere Medizin-Rheumatologie</name>
      <address>
        <city>Baden-Baden</city>
        <zip>76530</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Charité Mitte Charité Centrum 12. Med.Klinik Abt.Rheumatologie u.Klin.Immunologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schlosspark Klinik; Abt. Rheumatologie</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum &quot;Carl Gustav Carus&quot;; Medizinische Klinik III</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dres. Florian Schuch, Ruediger de la Camp, Martin Hammerschmidt u.w.</name>
      <address>
        <city>Erlangen</city>
        <zip>91056</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schön Klinik Hamburg-Eilbek Klinik für Rheumatologie</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis PD Dr.med. Bernhard Heilig</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum-Ruhrgebiet, St. Josefs-Krankenhaus; Rheumatologie</name>
      <address>
        <city>Herne</city>
        <zip>44652</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Von Hinueber/Dr. Demary; Rheumatologie</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik der Uni zu Köln; Klinik für Innere Medizin</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München; Bereich Pettenkoferstr.; Rheumaeinheit der medizinischen Klinik IV</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis an der Hase</name>
      <address>
        <city>Osnabrück</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Fachkrankenhaus; Rheumaklinik</name>
      <address>
        <city>Ratingen</city>
        <zip>40882</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg; Medizinische Klinik und Poliklinik II; Rheumatologie/Immunologie</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laiko General Hospital; Hematology Clinic</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larissa; Rheumatology Unit</name>
      <address>
        <city>Larissa</city>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Medica Del Dr Eduardo Alfredo Samayoa</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reuma-Centro</name>
      <address>
        <city>Guatemala City</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QUEEN MARY HOSPITAL; Division of Rheumatology &amp; Clinical Immunology</name>
      <address>
        <city>Hong Kong</city>
        <zip>852</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pamela Youde Nethersole Eastern Hospital; Department of Medicine</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital; Medicine &amp; Geriatrics</name>
      <address>
        <city>Tuen Mun</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Kórház KHT. II. Reumatológia</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Orvos- és Egészségtudományi Centrum; Belgyógyászati Intézet, Reumatológiai Tanszék</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markhot Ferenc Hospital; Dep. of Rheumatology</name>
      <address>
        <city>Eger</city>
        <zip>3300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork Uni Hospital; Dept of Rheumatology</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adelaide and Meath Hospital; Rheumatology Department</name>
      <address>
        <city>Dublin</city>
        <zip>24</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Vincent's University Hospital; Rheumatology Department</name>
      <address>
        <city>Dublin</city>
        <zip>4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haemek Hospital; Rheumatology</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai; Rheumatology</name>
      <address>
        <city>Ashkelon</city>
        <zip>78306</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnei Zion Medical Center; Rheumatology</name>
      <address>
        <city>Haifa</city>
        <zip>3339419</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital, Ein Karem; Rheumatology</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Mount Scopus Hospital; Rheumatology</name>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center; Internal Dept A</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center; Rheumatology</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center; Interna Dept B</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario; Cattedra Di Reumatologia, Edificio 3</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli; Unità di Reumatologia</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova; Reumatologia</name>
      <address>
        <city>Reggio Emilia</city>
        <state>Emilia-Romagna</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Bio-Medico; Immunologia e Allergologia</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I - Universita' La Sapienza ; Cattedra Di Reumatologia - Dept. Terapia Medica</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Degli Studi Di Genova - Dimi; Reumatologia</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Di Magenta Fornaroli; U.O. Di Reumatologia</name>
      <address>
        <city>Magenta</city>
        <state>Lombardia</state>
        <zip>20013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST FATEBENEFRATELLI SACCO; Reumatologia (Sacco)</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giovanni Bosco; S.C. A Direzione Uni Ria Di Immunologia Clinica</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10154</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Di Cagliari</name>
      <address>
        <city>Monserrato</city>
        <state>Sardegna</state>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Rheumatology; Clinical Centre Skopje</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación de Tratamientos Innovadores de Sinaloa (CITI)</name>
      <address>
        <city>Culiacán Rosales</city>
        <state>Sinaloa</state>
        <zip>80000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios de Investigacion Basica Y Clinica S.C.; Reumatologia</name>
      <address>
        <city>Guadalajara</city>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Reumatologia Rehabilitacion Integral; Centro Medico Del Angel</name>
      <address>
        <city>Mexicali</city>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad De Enfermedades; Cronico Degenerativas, SC.</name>
      <address>
        <city>Mexico</city>
        <zip>44620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliditer SA de CV</name>
      <address>
        <city>Miexico City</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación Clínica de Morelia, S.C.; Reumatologia</name>
      <address>
        <city>Morelia</city>
        <zip>58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Saltillo</name>
      <address>
        <city>Saltillo</city>
        <zip>25000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Enfermedades Reumaticas y Cronicodegenerativas</name>
      <address>
        <city>Torreon</city>
        <zip>27000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital, STAR Unit; Rheumatology Department</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital; Rheumatology Outpatients</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timaru Hospital</name>
      <address>
        <city>Timaru</city>
        <zip>7910</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Infusion Marbella; Consultorios Royal Center Num 214</name>
      <address>
        <city>Panama City</city>
        <zip>32400</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro especializado de rehabilitacion fisica y del dolor cerfid - unidad de inv. En reumatologia</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 14</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abk Reuma Srl- Medicentro</name>
      <address>
        <city>Lima</city>
        <zip>Lima 21</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Medicas/Hospital Maria Auxiliadora</name>
      <address>
        <city>San Juan de Miraflores</city>
        <zip>15801</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital; Rheumatology</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jose Reyes Memorial Medical Center</name>
      <address>
        <city>Manila</city>
        <zip>1003</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni of Santo Tomas Hospital; Rheumatology</name>
      <address>
        <city>Manila</city>
        <zip>1015</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny Nr 1; Oddzial Reumatologii I Rehabilitacji</name>
      <address>
        <city>Bytom</city>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zespolony; Oddzial Reumatologii</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ REUMED Sp. z o.o.</name>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medyczne Centrum Hetmanska; Indywidualna Specjalistyczna Praktyka Lekarska</name>
      <address>
        <city>Poznan</city>
        <zip>60-218</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Reumatologii I Chorób Wewn. Pum W Szczecinie; Samodzielny Publiczny Szpital Kliniczny Nr 1</name>
      <address>
        <city>Szczecin</city>
        <zip>71-252</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Reumatologii im. Prof. Dr hab. Eleonory Reicher; Oddzial Wczesnej Diagnostyki Stawow</name>
      <address>
        <city>Warszawa</city>
        <zip>02-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUC; Servico de Reumatologia</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria; Servico de Reumatologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sao Joao; Servico de Reumatologia</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce School of Medicine; Caimed Center</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Autonomous Institution of Healthcare &quot;City Clinical Hospital #40&quot;</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;National medico-surgical Centre n.a. N.I. Pirogov&quot; of the Ministry of Healthcare</name>
      <address>
        <city>Moscow</city>
        <zip>105203</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Scientific Research Institute of Rheumatology&quot; of russian Academy of Medical Sciences</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;FSCC of particularized sorts of medical care and medical technologies of FMBA&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBIH of Moscow &quot;City clinical hospital #1 n.a. N.I. Pirogov&quot; of Moscow Healthcare Department</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBIH of Moscow &quot;City Clinical Hospital #20 of Moscow Healthcare Department&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>129327</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan State Medical University Named after I.P.Pavlov</name>
      <address>
        <city>Ryazan</city>
        <zip>390011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI of HPE &quot;Northwestern State Medical University n.a. I.I.Mechnikov&quot; of MoH of RF</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State institution of healthcare &quot;Regional hospital for war veterans&quot;</name>
      <address>
        <city>Saratov</city>
        <zip>410002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution of Healthcare of Tula Region &quot;Tula Regional Clinical Hospital&quot;</name>
      <address>
        <city>Tula</city>
        <zip>300053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budget Institution of Healthcare of Voronezh Region &quot;Voronezh Regional Clinical Hospital #1&quot;</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution of Healthcare of Yaroslavl Region Clinical Hospital #8</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital; Dept of Medicine</name>
      <address>
        <city>Singapore</city>
        <zip>117599</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netcare Private Hospital</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Augustines Hospital; Rheumatology</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenacres Hospital</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6045</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Unit</name>
      <address>
        <city>Pretoria</city>
        <zip>0083</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winelands Research Centre</name>
      <address>
        <city>Stellenbosch</city>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Central de Asturias; Servicio de Reumatologia</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Merida ;Servicio de Reumatologia</name>
      <address>
        <city>Merida</city>
        <state>Badajoz</state>
        <zip>06800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla; Servicio de Reumatologia</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Reumatologia</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Sofia; Servicio de Reumatologia</name>
      <address>
        <city>San Sebastian de los Reyes</city>
        <state>Madrid</state>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia; Servicio de Reumatologia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Guadalajara; Servicio de Reumatologia</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa; Servicio de Reumatologia</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio; Servicio de Reumatologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Nuestra Señora de Valme; Servicio de Reumatologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital, Huddinge; Rheumatology</name>
      <address>
        <city>Huddinge</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Sjukhuset; Reumatologkliniken D2-1</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn Hospital; Division of Rheumatology - Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phramongkutklao Hospital; Dept. of Medicine, Rheumatology</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital, Mahidol Uni ; Allergy, Immunology &amp; Rheumatology, Dept of Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital; Department of Internal Medicine, Division of Rheumatology</name>
      <address>
        <city>Songkhla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iu Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali; Romatoloji Bilim Dali</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke'S Hospital; Rheumatology Research Unit</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cannock Chase Hospital; Rheumatology</name>
      <address>
        <city>Cannock</city>
        <zip>WS11 5XY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russells Hall Hospital; Rheumatology Department</name>
      <address>
        <city>Dudley</city>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital; Dept of Rheumatology</name>
      <address>
        <city>Maidstone</city>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trafford General Hospital; Rheumatology</name>
      <address>
        <city>Manchester</city>
        <zip>M41 5SL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary; Clinical Research Facility</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Tyneside General Hospital</name>
      <address>
        <city>North Shields</city>
        <zip>NE29 8NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital; Rheumatology</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haywood Hospital; Staffordshire Rheumatology Centre</name>
      <address>
        <city>Stoke-on-trent</city>
        <zip>ST6 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital; Dept of Rhematology</name>
      <address>
        <city>Torquay</city>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arrowe Park Hospital; Rheumatology Dept</name>
      <address>
        <city>Wirral</city>
        <zip>CH49 5PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2009</study_first_submitted>
  <study_first_submitted_qc>November 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2009</study_first_posted>
  <results_first_submitted>May 23, 2013</results_first_submitted>
  <results_first_submitted_qc>May 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2013</results_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Five of 1162 randomized patients (2 placebo to tocilizumab + methotrexate, 2 tocilizumab 4 mg/kg + methotrexate, 1 tocilizumab 8 mg/kg + methotrexate) did not receive any study treatment and were excluded from all analysis populations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo to Tocilizumab + Methotrexate</title>
          <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Tocilizumab 4 mg/kg + Methotrexate</title>
          <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Tocilizumab 8 mg/kg + Methotrexate</title>
          <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
          <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="290"/>
                <participants group_id="P3" count="291"/>
                <participants group_id="P4" count="292"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="231"/>
                <participants group_id="P3" count="227"/>
                <participants group_id="P4" count="236"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Therapeutic Response</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of Selection Criteria at Entry</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Treatment</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to Return</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics were based on the intent-to-treat (ITT) population. Five of 1162 randomized patients (2 placebo + methotrexate, 2 tocilizumab 4 mg/kg + methotrexate, 1 tocilizumab 8 mg/kg + methotrexate) did not receive any study treatment and were excluded from all analysis populations. The ITT population therefore included 1157 patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo to Tocilizumab + Methotrexate</title>
          <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Tocilizumab 4 mg/kg + Methotrexate</title>
          <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Tocilizumab 8 mg/kg + Methotrexate</title>
          <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
          <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="287"/>
            <count group_id="B2" value="288"/>
            <count group_id="B3" value="290"/>
            <count group_id="B4" value="292"/>
            <count group_id="B5" value="1157"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="13.10"/>
                    <measurement group_id="B2" value="51.2" spread="13.84"/>
                    <measurement group_id="B3" value="49.5" spread="13.70"/>
                    <measurement group_id="B4" value="49.9" spread="13.22"/>
                    <measurement group_id="B5" value="50.1" spread="13.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="228"/>
                    <measurement group_id="B3" value="228"/>
                    <measurement group_id="B4" value="219"/>
                    <measurement group_id="B5" value="904"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24</title>
        <description>A participant has a DAS28 remission response if their DAS28 &lt; 2.6. The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient’s global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.</description>
        <time_frame>Week 24</time_frame>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24</title>
          <description>A participant has a DAS28 remission response if their DAS28 &lt; 2.6. The DAS28 is a combined index for measuring disease activity in rheumatic arthritis (RA) and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient’s global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity [symptom-free and no arthritis symptoms], right end = maximum disease activity [maximum arthritis disease activity]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.</description>
          <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="288"/>
                <count group_id="O3" value="290"/>
                <count group_id="O4" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="10.9" upper_limit="19.1"/>
                    <measurement group_id="O2" value="31.9" lower_limit="26.6" upper_limit="37.3"/>
                    <measurement group_id="O3" value="44.8" lower_limit="39.1" upper_limit="50.6"/>
                    <measurement group_id="O4" value="38.7" lower_limit="33.1" upper_limit="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the DAS28 remission response at Week 24 between the placebo to tocilizumab + methotrexate and the tocilizumab 8 mg/kg + methotrexate treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A hierarchy of statistical testing was implemented in order to control the type I error rate for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The stratification factors, region and serologic status, were included in the model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.19</ci_lower_limit>
            <ci_upper_limit>7.14</ci_upper_limit>
            <estimate_desc>Last observation carried forward was used for TJC and SJC. No imputation was used for ESR and GH. Patients who withdrew prematurely or where a DAS28 could not be calculated were set to “non-responder”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the DAS28 remission response at Week 24 between the placebo to tocilizumab + methotrexate and the tocilizumab 8 mg/kg + placebo to methotrexate treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A hierarchy of statistical testing was implemented in order to control the type I error rate for multiple comparisons.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The stratification factors, region and serologic status, were included in the model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.47</ci_lower_limit>
            <ci_upper_limit>5.55</ci_upper_limit>
            <estimate_desc>Last observation carried forward was used for TJC and SJC. No imputation was used for ESR and GH. Patients who withdrew prematurely or where a DAS28 could not be calculated were set to “non-responder”.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in the DAS28 remission response at Week 24 between the placebo to tocilizumab + methotrexate and the tocilizumab 4 mg/kg + methotrexate treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A hierarchy of statistical testing was implemented in order to control the type I error rate for multiple comparisons. This comparison came after the break in statistical hierarchy.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>The stratification factors, region and serologic status, were included in the model.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.80</ci_lower_limit>
            <ci_upper_limit>4.11</ci_upper_limit>
            <estimate_desc>Last observation carried forward was used for TJC and SJC. No imputation was used for ESR and GH. Patients who withdrew prematurely or where a DAS28 could not be calculated were set to “non-responder”.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 52</title>
        <time_frame>Week 52</time_frame>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 52</title>
          <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="288"/>
                <count group_id="O3" value="290"/>
                <count group_id="O4" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5"/>
                    <measurement group_id="O2" value="34.0"/>
                    <measurement group_id="O3" value="49.0"/>
                    <measurement group_id="O4" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Weeks 24 and 52</title>
        <description>Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line “no disease activity” [symptom-free and no arthritis symptoms] and the extreme right end “maximum disease activity”; patient assessment of pain in previous the 24 hours on a VAS (extreme left end of the line “no pain” and the extreme right end “unbearable pain”); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.</description>
        <time_frame>Baseline to Weeks 24 and 52</time_frame>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With an Improvement ≥ 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20/50/70) From Baseline to Weeks 24 and 52</title>
          <description>Improvement must be seen in tender (68) and swollen (66) joint counts. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation. Improvement must also be seen in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the extreme left end of the line “no disease activity” [symptom-free and no arthritis symptoms] and the extreme right end “maximum disease activity”; patient assessment of pain in previous the 24 hours on a VAS (extreme left end of the line “no pain” and the extreme right end “unbearable pain”); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein (CRP), or erythrocyte sedimentation rate if CRP was missing.</description>
          <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="288"/>
                <count group_id="O3" value="290"/>
                <count group_id="O4" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24: ACR 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2"/>
                    <measurement group_id="O2" value="73.6"/>
                    <measurement group_id="O3" value="74.5"/>
                    <measurement group_id="O4" value="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: ACR 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2"/>
                    <measurement group_id="O2" value="47.9"/>
                    <measurement group_id="O3" value="56.9"/>
                    <measurement group_id="O4" value="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: ACR 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4"/>
                    <measurement group_id="O2" value="34.7"/>
                    <measurement group_id="O3" value="38.6"/>
                    <measurement group_id="O4" value="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: ACR 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="62.8"/>
                    <measurement group_id="O3" value="67.2"/>
                    <measurement group_id="O4" value="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: ACR 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8"/>
                    <measurement group_id="O2" value="52.4"/>
                    <measurement group_id="O3" value="55.9"/>
                    <measurement group_id="O4" value="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: ACR 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="37.2"/>
                    <measurement group_id="O3" value="43.1"/>
                    <measurement group_id="O4" value="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52</title>
        <description>The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint, including subluxation, is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52</title>
          <description>The mTSS is a measure of joint damage and includes measures of joint erosion (JE) and joint space narrowing (JSN). The JE score, using the van der Heijde modification, measures erosion severity in 32 hand joints and 12 foot joints. Each hand joint is scored from 0 to 5 and each foot joint is scored from 0 to 10; the total score ranges from 0 to 280. Each joint is scored according to the surface area involved. A score of 10 indicates extensive loss of bone from more than one-half of the articulating bone; a score of 0 indicates no erosion. The JSN score measures the severity of JSN in 30 hand joints (15 per hand) and 12 foot joints (6 per foot). Each joint, including subluxation, is scored from 0 to 4; the total score ranges from 0 to 168. A higher score indicates more joint space narrowing. The mTSS ranges from 0 to 448 (280+168). A higher mTSS score indicates greater damage. A negative change score indicates improvement.</description>
          <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="273"/>
                <count group_id="O4" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="4.297"/>
                    <measurement group_id="O2" value="0.42" spread="2.929"/>
                    <measurement group_id="O3" value="0.08" spread="2.090"/>
                    <measurement group_id="O4" value="0.26" spread="1.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Sharp Erosion Score at Week 52</title>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified Sharp Erosion Score at Week 52</title>
          <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="273"/>
                <count group_id="O4" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="2.556"/>
                    <measurement group_id="O2" value="0.25" spread="1.686"/>
                    <measurement group_id="O3" value="0.05" spread="1.736"/>
                    <measurement group_id="O4" value="0.15" spread="1.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sharp Joint Space Narrowing Score at Week 52</title>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sharp Joint Space Narrowing Score at Week 52</title>
          <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="268"/>
                <count group_id="O3" value="273"/>
                <count group_id="O4" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="2.362"/>
                    <measurement group_id="O2" value="0.17" spread="1.645"/>
                    <measurement group_id="O3" value="0.03" spread="0.751"/>
                    <measurement group_id="O4" value="0.11" spread="1.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Major Clinical Response at Week 52</title>
        <description>A major clinical response is defined as an ACR70 response that is maintained for 6 consecutive months (24 weeks) for any 24-week period between Week 2 and Week 52.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Major Clinical Response at Week 52</title>
          <description>A major clinical response is defined as an ACR70 response that is maintained for 6 consecutive months (24 weeks) for any 24-week period between Week 2 and Week 52.</description>
          <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="288"/>
                <count group_id="O3" value="290"/>
                <count group_id="O4" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Weeks 24 and 52</title>
        <description>The Stanford HAQ-DI is a patient completed questionnaire specific for rheumatoid arthritis. The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.</description>
        <time_frame>Baseline to Weeks 24 and 52</time_frame>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Weeks 24 and 52</title>
          <description>The Stanford HAQ-DI is a patient completed questionnaire specific for rheumatoid arthritis. The HAQ-DI assesses how well the patient is able to perform 8 activities: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The patient answers 20 questions with 1 of 4 responses with the past week as the time frame: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The highest score for any question in a category determines the category score. The total score ranges from 0 (no disability) to 3 (completely disabled). A negative change score indicates improvement.</description>
          <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="288"/>
                <count group_id="O3" value="290"/>
                <count group_id="O4" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (n=246, 255, 250, 265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.718"/>
                    <measurement group_id="O2" value="-0.92" spread="0.736"/>
                    <measurement group_id="O3" value="-0.91" spread="0.695"/>
                    <measurement group_id="O4" value="-0.82" spread="0.739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=214, 227, 228, 230)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.800"/>
                    <measurement group_id="O2" value="-1.00" spread="0.795"/>
                    <measurement group_id="O3" value="-0.97" spread="0.700"/>
                    <measurement group_id="O4" value="-0.87" spread="0.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short Form 36 (SF-36) Physical Component Summary (PCS) Scores at Weeks 24 and 52</title>
        <description>The SF-36 Health Survey (Version 2) is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL.</description>
        <time_frame>Baseline to Weeks 24 and 52</time_frame>
        <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo to Tocilizumab + Methotrexate</title>
            <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tocilizumab 4 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab 8 mg/kg + Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
            <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short Form 36 (SF-36) Physical Component Summary (PCS) Scores at Weeks 24 and 52</title>
          <description>The SF-36 Health Survey (Version 2) is a standardized questionnaire consisting of 36 questions that measures patient-reported symptoms on 8 dimensions; it is used to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL.</description>
          <population>Intent-to-treat population: All randomized participants who received at least 1 tocilizumab/placebo infusion.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="288"/>
                <count group_id="O3" value="290"/>
                <count group_id="O4" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (n=237, 247, 246, 255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.35" spread="9.763"/>
                    <measurement group_id="O2" value="11.33" spread="9.282"/>
                    <measurement group_id="O3" value="12.13" spread="9.263"/>
                    <measurement group_id="O4" value="10.75" spread="10.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=204, 225, 221, 224)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.72" spread="10.389"/>
                    <measurement group_id="O2" value="12.27" spread="10.509"/>
                    <measurement group_id="O3" value="13.52" spread="9.848"/>
                    <measurement group_id="O4" value="11.73" spread="10.691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from Baseline through Week 52.</time_frame>
      <desc>Safety population: All patients who received at least 1 tocilizumab/placebo infusion and had at least 1 post-dose safety assessment. 7 patients were excluded from the safety population (no treatment received or no post-baseline safety data). The total safety population included 1153 patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo to Tocilizumab + Methotrexate</title>
          <description>Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Tocilizumab 4 mg/kg + Methotrexate</title>
          <description>Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Tocilizumab 8 mg/kg + Methotrexate</title>
          <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Tocilizumab 8 mg/kg + Placebo to Methotrexate</title>
          <description>Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Myocardial fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Neurosensory hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pneumococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Oteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Endometrial cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Metastatic bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Renal cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Epididymal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="201" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="163" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="282"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="290"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

